查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858094

肉瘤药物市场按药物类别、适应症、给药途径、最终用户和治疗方式划分－2025-2032年全球预测

Sarcoma Drugs Market by Drug Class, Indication, Route Of Administration, End User, Treatment Modality - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肉瘤治疗市场将成长至 31.6 亿美元，复合年增长率为 8.35%。

主要市场统计数据
基准年 2024 16.6亿美元
预计年份：2025年 18亿美元
预测年份：2032年 31.6亿美元
复合年增长率 (%) 8.35%

将科学进展与不同疾病类型的临床、监管和商业性现实相结合，为肉瘤药物策略奠定了基础。

肉瘤治疗是肿瘤学领域最复杂、技术要求最高的领域之一，涵盖罕见组织学类型、异质性分子驱动因素和治疗途径，需要多学科协作。本执行摘要首先将肉瘤置于更广泛的肿瘤学生态系统中进行阐述。在这个治疗领域，分子标靶疗法、免疫肿瘤治疗方法和复杂的细胞毒性方案与基因组学和组织病理学的诊断进展相交织。围绕临床开发、监管策略和市场准入的决策必须考虑到异质性患者群体、不断发展的生物标记范式以及不断变化的支付方预期。

分子谱分析、适应性测试设计和监管务实主义的进步如何重塑肉瘤药物研发路径和商业策略

在科学、监管和商业性力量的共同推动下，肉瘤领域正经历着一场变革性的转变，相关人员对计画优先顺序的设定和资源的分配方式也随之改变。在科学层面，基因组分析和单细胞技术的进步加速了标靶发现和患者分层，使得针对分子定义的队列进行小规模、更有效率、信噪比更高的检测成为可能。同时，细胞疗法和免疫肿瘤联合治疗的成熟，正在拓展传统细胞毒性疗法以外的潜在治疗途径。这些进展正在改变检测设计的基本原理，促进适应性方案和平台检测的开发，缩短检测週期，并提升对罕见亚型的认识。

美国关税趋势至2025年对肉瘤药物商业化供应链韧性、筹资策略和价格谈判的影响

美国关税的累积效应（效应将持续到2025年）为参与肉瘤治疗药物研发和分销的赞助商、製造商和医疗保健系统带来了新的考量。影响原料药、关键材料和某些医疗设备的关税可能导致供应链成本上升，并促使企业重新评估筹资策略和生产布局。为了减轻进口关税的影响并维持可预测的生产前置作业时间，製造商通常会优化供应商网路、在原料药采购方面建立冗余机制，并加快对区域製造的投资。

一个多维度细分框架，将药物类别、适应症、给药途径、最终用户和治疗方式连结起来，以辅助优先排序和营运规划。

细分市场分析揭示了相关人员可以从多个角度确定投资优先顺序并调整开发计划。依药物类别划分，抗血管新生疗法、化疗、荷尔蒙疗法、免疫疗法和标靶治疗是主要类别；抗血管新生疗法可分为血小板衍生生长因子（PDGF）抑制剂和血管内皮生长因子（VEGF）抑制剂；化疗可分为烷化剂、细胞週期蛋白类药物、抗代谢药物和拓朴异构酶抑制剂；免疫疗法可分为过继性细胞疗法、癌症疫苗、查核点抑制剂和细胞激素疗法；标靶治疗可分为CDK4/6抑制剂、mTOR抑制剂、PARP抑制剂和蛋白酪氨酸激酶抑制剂。每类药物都有不同的临床试验设计、安全性监测需求、生产复杂性和支付价值提案，因此开发团队需要根据适应症和预期治疗方案选择药物。

关键区域监管差异、临床能力和报销现状如何影响战略部署计划和证据生成优先事项。

区域动态对肉瘤治疗药物的临床开发、监管策略和商业性实施有显着影响。美洲地区拥有先进的诊断基础设施、完善的临床实验室网络，以及要求提供清晰成本效益报告的支付方环境，这些因素共同使其成为註册研究和早期商业上市的重点区域。放眼欧洲、中东和非洲，相关人员会发现监管管道多元、报销体系各异，诊断能力也参差不齐。在这些地区取得成功通常需要模组化的准入策略，以弥补国家卫生技术评估流程和罕见疾病中心能力方面的不足。在亚太地区，癌症研究的快速投入、临床试验参与度的提高以及报销体系的演变，既带来了机会，也带来了挑战，因此需要特别关注本地化生产、区域监管协调以及符合当地文化习惯的患者参与方式。

平衡创新与规模：跨国开发商、领先生技公司与合作伙伴关係模式在推动肉瘤药物研发的策略优势

肉瘤治疗领域的竞争格局融合了成熟的跨国肿瘤公司的规模和研发能力，以及专业生物技术企业的敏捷性和对特定分子的专注。拥有强大研发能力的大型製药企业具备丰富的研发经验、全球监管经验和整合的商业管道，能够加速后期专案的上市。它们的优势包括能够承保大规模註册项目并协商复杂的支付方协议。相较之下，规模较小的生物技术公司通常透过利基机制推动创新，快速迭代以生物标誌物为导向的策略，并为寻求补充其产品组合的大型公司创造高价值的合作机会。因此，策略联盟、授权协议和联合开发伙伴关係关係十分常见，这使得联合策略得以实施，并实现了公司间专业生产和临床技术的共享。

对于肉瘤计画而言，开发人员和相关人员在临床设计、供应弹性、支付方证据产生和伙伴关係管治方面需要采取切实可行的策略措施。

产业领导者应采取果断行动，在管控商业和营运风险的同时，将科学前景转化为持续的患者获益。首先，透过将早期研发与明确的市场推广假设结合，减少浪费性投资并加快与支付方的沟通。这些假设应明确目标组织、生物标记策略和理想的治疗环境。其次，投资于模组化、适应性强的测试设计，以便在分子定义的队列中进行假设检验，加快概念验证的公布，并保留免疫疗法和标靶药物联合治疗策略的选择。第三，透过原料药来源多元化、探索区域性生产伙伴关係关係以及检验依赖器械给药途径的应急计画，建构具有韧性的供应链，以减轻关税和物流中断的影响。

结合专家访谈、二手证据三角验证和情境分析等多种方法的稳健混合研究途径，确保了研究结果具有可操作性和可复製性。

本研究整合了专家访谈、文献回顾以及对临床、监管和商业性讯号的结构化分析，旨在全面展现肉瘤治疗领域的现况。一级资讯来源包括对肿瘤内科医生、临床检验医师、监管专家和市场准入专家的访谈，以解读临床实践模式和支付方预期所反映的科学和商业趋势。二级资讯来源包括同行评审的临床文献、监管指南、会议论文集以及药物研发技术文件，这些资料经过三角验证，以检验研究结果并为新兴治疗方法提供背景资讯。

整合策略重点，将科学进步转化为可持续的临床影响，并预测肉瘤领域在营运、监管和支付方面面临的挑战

最后，肉瘤治疗领域展现出令人着迷的科学机会与实际复杂性的交织。分子表征、免疫疗法设计和联合疗法的进步正在拓展可行的治疗策略，但成功与否取决于临床开发、监管规划和商业性化准备的严格协调。按药物类别、适应症、给药途径、治疗方式和最终用户进行精准细分，将有助于集中资源并提高检测效率。区域策略必须体现诊断能力、监管管道和支付方期望方面的差异，而面对关税和地缘政治压力，供应链的韧性也变得日益重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 标靶蛋白酪氨酸激酶抑制剂的进展改善了肉瘤患者的生存结果
  • 快速发展的基因组分析技术使得个人化肉瘤治疗方案成为可能。
  • 将免疫疗法和化疗整合到晚期肉瘤药物研发管线中。
  • 一种新型双特异性抗体，针对两种肉瘤抗原，目前正处于临床前和临床试验阶段。
  • 监管突破加速罕见软组织肉瘤亚型孤儿药的核准
  • 针对抗药性肉瘤细胞通道的新一代mTOR抑制剂进入市场
  • 提高肉瘤药物定价和报销策略中真实世界证据的采纳率

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肉瘤药物市场（依药物类别划分）

  • 抗血管新生疗法
    • PDGF抑制剂
    • VEGF抑制剂
  • 化疗
    • 烷化剂
    • 细胞週期蛋白
    • 抗代谢物
    • 拓朴异构酶抑制剂
  • 荷尔蒙疗法
  • 免疫疗法
    • 过继性细胞疗法
    • 癌症疫苗
    • 查核点抑制剂
    • 细胞激素疗法
  • 标靶治疗
    • CDK4/6抑制剂
    • MTOR抑制剂
    • PARP抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章 肉瘤药物市场（依适应症划分）

  • 骨癌
    • 软骨肉瘤
    • 伊文氏肉瘤
    • 骨癌
  • 胃肠道基质肿瘤
  • 卡波西氏肉瘤
  • 软组织肉瘤
    • 平滑肌肉瘤
    • 脂肪肉瘤
    • 横纹肌肉瘤
    • 滑膜肉瘤

第十章 按给药途径分類的肉瘤药物市场

  • 肌肉内注射
  • 静脉
  • 口服
  • 皮下

第十一章 按最终用户分類的肉瘤药物市场

  • 门诊手术中心
  • 居家医疗
  • 医院
  • 专科诊所

第十二章 肉瘤药物市场依治疗方式划分

  • 联合治疗
    • 化疗+免疫疗法
    • 化疗合併标标靶治疗
    • 免疫疗法合併标标靶治疗
  • 单药治疗

第十三章 各地区肉瘤药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肉瘤药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国肉瘤药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • Ipsen SA
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Deciphera Pharmaceuticals, LLC
    • Blueprint Medicines Corporation
    • Epizyme, Inc.
    • Merck & Co., Inc.
Product Code: MRR-C002B1C996FA

The Sarcoma Drugs Market is projected to grow by USD 3.16 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.66 billion
Estimated Year [2025] USD 1.80 billion
Forecast Year [2032] USD 3.16 billion
CAGR (%) 8.35%

Setting the context for sarcoma therapeutics strategy by aligning scientific advances with clinical, regulatory and commercial realities across heterogeneous disease types

Sarcoma therapeutics represent one of oncology's most complex and technically demanding areas, spanning rare histologies, heterogeneous molecular drivers and treatment pathways that require multidisciplinary coordination. This executive summary opens by situating sarcoma within the broader oncology ecosystem: a therapeutic domain where targeted molecular approaches, immuno-oncology modalities and refined cytotoxic regimens intersect with diagnostic advances in genomics and histopathology. The practical consequences for developers and health system stakeholders are profound; decisions around clinical development, regulatory strategy and market access must incorporate heterogeneous patient populations, evolving biomarker frameworks and shifting payer expectations.

Clinical progress has been uneven by histologic subtype, but recent years have delivered a richer understanding of disease biology, enabling more precise interventions in previously intractable presentations. Consequently, stakeholders must balance long-standing standards of care with novel mechanisms that may offer incremental or transformational benefit depending on the indication. This introduction frames the remainder of the analysis by highlighting the interplay of scientific innovation, stakeholder incentives and operational constraints that shape strategic choices across drug class, indication, administration route and treatment modality. It also underscores the imperative for commercially minded teams to integrate cross-functional intelligence-clinical, regulatory, supply chain and reimbursement-to navigate a fast-moving therapeutic landscape effectively.

How advances in molecular profiling, adaptive trial design, and regulatory pragmatism are reshaping development pathways and commercial strategies in sarcoma therapeutics

The sarcoma landscape is undergoing transformative shifts driven by converging scientific, regulatory and commercial forces that are reshaping how stakeholders prioritize programs and allocate resources. At the scientific level, enhanced genomic profiling and single-cell technologies have accelerated target discovery and patient stratification, enabling smaller, more efficient trials with higher signal-to-noise for molecularly defined cohorts. Concurrently, the maturation of cell therapy and combination immuno-oncology strategies is expanding the set of plausible therapeutic pathways beyond traditional cytotoxic regimens. These advances are changing trial design fundamentals, encouraging adaptive protocols and platform trials that reduce timelines and improve learning across rare subtypes.

From a regulatory perspective, agencies are signaling greater willingness to engage on novel endpoints, accelerated approval pathways and conditional licensing for rare diseases, provided there is robust post-approval evidence generation. This regulatory pragmatism incentivizes earlier and clearer alignment between developers and regulators on surrogate endpoints, real-world evidence collection and risk mitigation strategies. Commercially, payers and procurement systems are increasingly demanding transparent value narratives and outcomes-based contracting for high-cost interventions, which favors developers who can demonstrate durable benefit and manageable safety profiles. Together, these shifts underscore a new operating model for sarcoma programs: rapid biomarker-enabled segmentation, flexible clinical proof-of-concept approaches, and integrated downstream planning for access and lifecycle management.

Implications of US tariff dynamics through 2025 for supply chain resilience, sourcing strategies, and pricing negotiations in sarcoma drug commercialization

The cumulative effect of United States tariff measures implemented through 2025 has introduced new considerations for sponsors, manufacturers and health systems engaged in sarcoma drug development and distribution. Tariffs affecting active pharmaceutical ingredients, critical raw materials and certain medical equipment can raise incremental costs along the supply chain, prompting reassessments of sourcing strategies and manufacturing footprints. In many cases, manufacturers respond by re-optimizing supplier networks, building redundancy into API sourcing and accelerating regional manufacturing investments to mitigate exposure to import levies and to preserve predictable production lead times.

Beyond direct cost impacts, tariffs influence commercial negotiation dynamics with payers and distributors. Where reimbursement is tightly constrained, even modest cost increases can alter pricing strategies and contract terms. Procurement teams may prioritize suppliers with localized supply chains to reduce tariff-related volatility, and developers may find added leverage in forming toll-manufacturing partnerships or licensing arrangements that localize production closer to end markets. Regulatory clearance processes and quality oversight remain paramount; any rapid manufacturing relocation must maintain compliance with Good Manufacturing Practice and ensure supply continuity for patients with few therapeutic alternatives. Ultimately, the tariff environment increases the strategic value of robust supply chain planning, scenario modeling and early engagement with procurement and manufacturing partners to safeguard access and preserve commercial viability.

A multidimensional segmentation framework linking drug classes, indications, administration routes, end users and treatment modalities to inform prioritization and operational planning

Segmentation analysis reveals multiple lenses through which stakeholders can prioritize investment and tailor development plans. When examining drug class, key categories include Antiangiogenic Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy; Antiangiogenic Therapy subdivides into PDGF Inhibitors and VEGF Inhibitors, Chemotherapy further separates into Alkylating Agents, Anthracyclines, Antimetabolites, and Topoisomerase Inhibitors, Immunotherapy encompasses Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, and Cytokine Therapy, and Targeted Therapy includes CDK4/6 Inhibitors, MTOR Inhibitors, PARP Inhibitors, and Tyrosine Kinase Inhibitors. Each drug-class grouping implies different clinical trial designs, safety monitoring needs, manufacturing complexity and payer value propositions, so development teams should align modality selection with the intended indication and expected line of therapy.

Indication-based segmentation distinguishes Bone Sarcoma, Gastrointestinal Stromal Tumors, Kaposi Sarcoma, and Soft Tissue Sarcoma; within Bone Sarcoma, clinicians and developers consider Chondrosarcoma, Ewing Sarcoma, and Osteosarcoma as distinct biological entities with differing therapeutic responsiveness, while Soft Tissue Sarcoma includes Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, and Synovial Sarcoma, each demanding tailored clinical endpoints and histology-specific consideration. Route of administration segmentation covers Intramuscular, Intravenous, Oral, and Subcutaneous options, which shape patient adherence expectations, outpatient versus inpatient delivery models, and device or formulation development needs. End user segmentation identifies Ambulatory Surgical Centers, Home Care environments, Hospitals, and Specialty Clinics as primary delivery settings, influencing channel strategies, training requirements and reimbursement pathways. Treatment modality differentiation between Combination Therapy and Monotherapy, with Combination Therapy including Chemotherapy Plus Immunotherapy, Chemotherapy Plus Targeted, and Immunotherapy Plus Targeted approaches, drives decisions on clinical coordination, safety overlap management and commercial collaboration frameworks between co-developers. By integrating these segmentation axes, organizations can map development choices to operational constraints and market access realities, enabling prioritized investments where clinical need, biological plausibility and practicable deployment converge.

How regional regulatory diversity, clinical capacity and reimbursement realities across major geographies shape strategic rollout plans and evidence generation priorities

Regional dynamics materially influence clinical development, regulatory strategy and commercial execution across sarcoma therapeutics. In the Americas, the landscape is characterized by advanced diagnostic infrastructure, well-established clinical trial networks and a payer environment that demands clear cost-effectiveness narratives, which together make it a focal point for registrational studies and early commercial launches. Transitioning to Europe, Middle East & Africa, stakeholders encounter diverse regulatory pathways, heterogenous reimbursement systems and varying levels of diagnostic capability; success in this region often requires modular access strategies that address country-level HTA processes and capacity gaps in rare disease centers of excellence. In the Asia-Pacific region, rapid investment in oncology research, expanding clinical trial participation and evolving reimbursement frameworks create both opportunity and complexity, with particular attention needed on local manufacturing, regional regulatory harmonization and culturally appropriate patient engagement.

Across these geographic areas, clinical trial enrollment logistics, availability of specialized sarcoma centers, and regional variations in histologic prevalence all shape trial feasibility and post-approval adoption. Accordingly, successful programs adopt phased regional strategies that leverage early wins in capacity-dense markets while simultaneously investing in evidence generation, local stakeholder engagement and manufacturing adjustments to support broader rollout. This geographically nuanced approach helps ensure that clinical data, regulatory submissions and commercial readiness progress in parallel and that regional reimbursement barriers are anticipated and addressed proactively.

Balancing innovation and scale: the strategic advantages of multinational developers, nimble biotechs, and collaborative partnership models in advancing sarcoma therapies

The competitive landscape in sarcoma therapeutics blends the scale and development capacity of established multinational oncology firms with the agility and molecular focus of specialty biotechs. Large pharma players bring extensive development expertise, global regulatory experience, and integrated commercial channels that accelerate late-stage programs to market; their strengths include ability to underwrite expansive registrational programs and to negotiate complex payer arrangements. In contrast, smaller biotech companies often drive innovation in niche mechanisms, rapidly iterate on biomarker-directed strategies, and create high-value partnering opportunities for larger organizations seeking to complement their portfolios. Strategic alliances, licensing deals and co-development partnerships are therefore common, enabling combination strategies and cross-company access to specialized manufacturing or clinical expertise.

Investors and corporate development teams should track not only pipeline breadth but also platform capabilities, biomarker development resources, and manufacturing readiness. Companies with strong translational medicine functions and access to comprehensive patient registries and histology-specific networks are better positioned to execute small, high-impact trials. Additionally, firms that demonstrate operational excellence in cell therapy logistics, companion diagnostic co-development, or novel formulation delivery stand to differentiate in commercialization discussions with payers and providers. Ultimately, winning companies will combine scientific differentiation with pragmatic execution: robust clinical programs, validated companion diagnostics where appropriate, and credible commercialization blueprints that address the end-to-end patient journey.

Practical strategic imperatives for developers and stakeholders to align clinical design, supply resilience, payer evidence generation and partnership governance for sarcoma programs

Industry leaders should act decisively to translate scientific promise into durable patient benefit while managing commercial and operational risk. First, align early-stage development with a clear go-to-market hypothesis that defines target histologies, biomarker strategies and preferred care settings; this alignment reduces wasted investment and accelerates payer conversations. Second, invest in modular and adaptive trial designs that enable hypothesis testing across molecularly defined cohorts, accelerate proof-of-concept readouts and preserve optionality for combination strategies with immunotherapies or targeted agents. Third, build resilient supply chains by diversifying API sources, considering regional manufacturing partnerships, and validating contingency plans for device-dependent administration routes to mitigate tariffs and logistical disruptions.

In parallel, prioritize evidence generation that meets payer needs: integrate health economics endpoints and quality-of-life measures into pivotal development programs, and plan for real-world data collection that supports durability claims post-approval. Engage payers, providers and centers of excellence early to shape acceptable endpoints and to secure pathways for access. For companies pursuing combination strategies, establish clear co-development agreements that align incentives and responsibilities for safety monitoring, data sharing and commercialization. Finally, strengthen patient engagement and advocacy partnerships to streamline trial recruitment, enhance retention and incorporate patient-centric outcomes into product value narratives. These combined actions will improve the probability of regulatory success, accelerate market adoption and foster sustainable value capture.

A robust mixed-methods research approach combining primary expert elicitation, secondary evidence triangulation, and scenario-based analysis to ensure actionable and reproducible insights

This research synthesizes primary expert interviews, secondary literature review and structured analysis of clinical, regulatory and commercial signals to provide a comprehensive view of the sarcoma therapeutic landscape. Primary inputs included interviews with oncologists, clinical trial investigators, regulatory experts and market access professionals, ensuring that clinical practice patterns and payer expectations informed interpretation of scientific and operational trends. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidances, conference proceedings and technical drug development resources; these materials were triangulated to validate insights and to contextualize emerging therapeutic modalities.

Analytical methods combined qualitative thematic analysis with cross-sectional mapping of segmentation axes to reveal where biological plausibility, clinical need and operational feasibility intersect. Scenario analysis was used to explore the implications of supply chain shocks and tariff pressures on manufacturing and pricing strategies, while comparative benchmarking illuminated differentiators among developer archetypes. Throughout, emphasis was placed on transparent assumptions, reproducible workflows, and clear traceability between cited evidence and strategic conclusions. The methodology supports replicable updates as new clinical data, regulatory decisions or commercial developments emerge, enabling stakeholders to refresh strategies in response to evolving evidence.

Synthesis of strategic priorities for translating scientific advances into sustainable clinical impact while anticipating operational, regulatory and payer challenges in sarcoma

In closing, the sarcoma therapeutics arena presents a compelling mix of scientific opportunity and practical complexity. Progress in molecular characterization, immunotherapy design and combination approaches has expanded the set of viable therapeutic strategies, but success depends on disciplined alignment of clinical development, regulatory planning and commercial preparation. Robust segmentation-across drug class, indication, route of administration, treatment modality and end user-enables focused resource allocation and more efficient trial execution. Regional strategies must reflect differences in diagnostic capacity, regulatory pathways and payer expectations, and supply chain resilience is increasingly important in the face of tariff and geopolitical pressures.

Organizations that integrate translational science with adaptive trial design, build strategic partnerships to close capability gaps, and engage payers and patients early will be best positioned to translate innovation into sustained clinical and commercial impact. Thoughtful investment in evidence that demonstrates real-world value and in operations that secure reliable supply will accelerate adoption and improve outcomes for patients living with these rare and often aggressive diseases. The path forward requires both scientific rigor and pragmatic execution, and the recommendations offered here provide a framework to convert insight into effective action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in targeted tyrosine kinase inhibitors improving sarcoma survival outcomes
  • 5.2. Rapidly evolving genomic profiling techniques enabling personalized sarcoma drug regimens
  • 5.3. Integration of immunotherapy combinations with chemotherapy in advanced sarcoma treatment pipelines
  • 5.4. Emerging bispecific antibodies targeting dual sarcoma antigens in preclinical and clinical trials
  • 5.5. Regulatory breakthroughs accelerating orphan drug approvals for rare soft tissue sarcoma subtypes
  • 5.6. Market entry of next generation mTOR inhibitors targeting resistant sarcoma cell pathways
  • 5.7. Increasing adoption of real world evidence to inform sarcoma drug pricing and reimbursement strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sarcoma Drugs Market, by Drug Class

  • 8.1. Antiangiogenic Therapy
    • 8.1.1. PDGF Inhibitors
    • 8.1.2. VEGF Inhibitors
  • 8.2. Chemotherapy
    • 8.2.1. Alkylating Agents
    • 8.2.2. Anthracyclines
    • 8.2.3. Antimetabolites
    • 8.2.4. Topoisomerase Inhibitors
  • 8.3. Hormonal Therapy
  • 8.4. Immunotherapy
    • 8.4.1. Adoptive Cell Therapy
    • 8.4.2. Cancer Vaccines
    • 8.4.3. Checkpoint Inhibitors
    • 8.4.4. Cytokine Therapy
  • 8.5. Targeted Therapy
    • 8.5.1. CDK4/6 Inhibitors
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. PARP Inhibitors
    • 8.5.4. Tyrosine Kinase Inhibitors

9. Sarcoma Drugs Market, by Indication

  • 9.1. Bone Sarcoma
    • 9.1.1. Chondrosarcoma
    • 9.1.2. Ewing Sarcoma
    • 9.1.3. Osteosarcoma
  • 9.2. Gastrointestinal Stromal Tumors
  • 9.3. Kaposi Sarcoma
  • 9.4. Soft Tissue Sarcoma
    • 9.4.1. Leiomyosarcoma
    • 9.4.2. Liposarcoma
    • 9.4.3. Rhabdomyosarcoma
    • 9.4.4. Synovial Sarcoma

10. Sarcoma Drugs Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Sarcoma Drugs Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Sarcoma Drugs Market, by Treatment Modality

  • 12.1. Combination Therapy
    • 12.1.1. Chemotherapy Plus Immunotherapy
    • 12.1.2. Chemotherapy Plus Targeted
    • 12.1.3. Immunotherapy Plus Targeted
  • 12.2. Monotherapy

13. Sarcoma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sarcoma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sarcoma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Bayer AG
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Ipsen S.A.
    • 16.3.5. Eisai Co., Ltd.
    • 16.3.6. Eli Lilly and Company
    • 16.3.7. Deciphera Pharmaceuticals, LLC
    • 16.3.8. Blueprint Medicines Corporation
    • 16.3.9. Epizyme, Inc.
    • 16.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY R